Denovo Biotherapeutics is developing an mRNA-encoded treatment technology that produces bispecific antibodies to target relapsed or refractory lymphoma, enhancing the recruitment of natural killer (NK) cells. This approach aims to facilitate the discovery of new drug candidates, addressing the need for effective therapies in challenging cancer cases.
Funding
Funding not disclosed
Founders
Product
Problem
Relapsed or refractory lymphomas present significant therapeutic challenges due to their resistance to conventional treatments. The need for innovative approaches to enhance the efficacy of cancer therapies and discover new drug candidates remains critical.
Solution
Denovo Biotherapeutics is developing an mRNA-based platform to produce bispecific antibodies for the treatment of relapsed or refractory cancers. This technology aims to enhance the recruitment of natural killer (NK) cells to tumor sites, thereby improving the anti-cancer immune response. By leveraging mRNA technology, Denovo Biotherapeutics seeks to create more affordable and effective biotherapeutics. The company is designing mRNA engagers with novel targets and plans to prioritize lead candidates for clinical studies.
Target Audience
The primary target audience includes patients with relapsed or refractory lymphomas, as well as oncologists and researchers seeking innovative treatment options.
Features
- mRNA-encoded bispecific antibody production
- Enhanced recruitment of natural killer (NK) cells to target tumors
- Focus on relapsed or refractory lymphoma treatment
- Novel target identification for mRNA engagers
- Streamlined drug discovery process